2020 Annual Global Meeting: Virtual-Master Session: Uterine Cancer

Video Transcription

Video Summary

Summary of the first video:<br />The video focuses on the significance of low-volume metastasis in sentinel lymph nodes of endometrial cancer patients. Various studies examining the outcomes of patients with isolated tumor cells (ITCs) and micrometastases are reviewed, but the limited data and retrospective nature of the studies underscore the need for longer follow-up and further research. The effectiveness of adjuvant treatment for patients with low-volume metastasis is assessed using institutional and multi-institutional data, with varying results suggesting the need for personalized treatment decisions based on risk factors and histology.<br /><br />Summary of the second video:<br />Dr. Mansoor Mirza discusses current and future directions in managing advanced recurrent endometrial cancer. The standard chemotherapy regimen of paclitaxel and carboplatin is highlighted, but limited treatment options beyond this exist. Challenges in hormonal therapy and the lack of level one evidence are discussed. The addition of anti-angiogenic agents like bevacizumab to chemotherapy has shown mixed results. Ongoing trials investigate targeted agents such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors. The promising role of immune therapy is emphasized, particularly with checkpoint inhibitors like dostarlimab in both MSI-high and MSS tumors. The combination of immune therapy and targeted agents, like pembrolizumab and lenvatinib, is also explored. Dr. Mirza advocates for more targeted therapies and personalized treatment strategies, mentioning ongoing trials based on molecular profiling and biomarkers as the future of endometrial cancer treatment.<br /><br />Credits:<br />Video 1: No specific credits mentioned.<br />Video 2: Presented by Dr. Mansoor Mirza.

Keywords

low-volume metastasis

sentinel lymph nodes

endometrial cancer

isolated tumor cells

micrometastases

adjuvant treatment

institutional data

risk factors

histology

chemotherapy regimen

hormonal therapy

anti-angiogenic agents

immune therapy

checkpoint inhibitors

targeted agents